| Name | Title | Contact Details |
|---|
InterHealth Nutraceuticals, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. InterHealth Nutraceuticals, Inc is based in Benicia, CA. You can find more information on InterHealth Nutraceuticals, Inc at www.interhealthusa.com
Healthcare Interactive, Inc. (HCIactive) is dedicated to revolutionizing the administration and delivery of healthcare. Through our patented, integrative technology and supplemental ancillary services, we afford clients the freedom, control and energy to provide high-performance plan solutions that mitigate risk and improve member outcomes. Disparate plan functions, such as enrollment and eligibility, incentive management and population health are seamlessly conducted through our single-source, cloud-based platform. The outcome: greater operational efficiency, actionable performance data, increased member participation, and overall reduced healthcare costs. Founded in 2006, HCIactive is the progressive leader in delivering integrated, health plan solutions to TPA`s, brokers, health systems, providers and their customers. Our executive leadership team is comprised of seasoned professionals who have established successful track-records in the healthcare industry with over 85 years of combined experience.
Corexcel is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medifacts International, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.